By Colin Kellaher
Zevra Therapeutics has inked a deal to sell its Food and Drug Administration priority-review voucher to an undisclosed buyer for gross proceeds of $150 million.
Zevra, which won the voucher upon FDA approval of its Miplyffa drug for the rare neurodegenerative disorder Niemann-Pick disease type C, on Thursday said it expects to complete the sale within 30 to 45 days.
The FDA awards the vouchers upon approval of drugs previously granted rare-pediatric-disease designation, and they can be used to obtain priority review for another drug or sold to other companies. Acadia Pharmaceuticals and PTC Therapeutics last year struck deals to sell vouchers for $150 million apiece.
Zevra, a Celebration, Fla., rare-disease company, said it will use the sale proceeds to support the commercial launches of its Miplyffa and Olpruva drugs and to advance its pipeline of product candidates.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
February 27, 2025 10:14 ET (15:14 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。